I. Tempera

发表

CTCF binding site sequence differences are associated with unique regulatory and functional trends during embryonic stem cell differentiation

S. Hannenhalli, R. Davuluri, Robert N. Plasschaert, 2013, Nucleic acids research.

An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions.

Christina Leslie, Aaron Arvey, C. Leslie, 2012, Cell host & microbe.

HIV-1 Vpr disrupts mitochondria axonal transport and accelerates neuronal aging

I. Tempera, Kayla A. Martin, B. Sawaya, 2017, Neuropharmacology.

Alterations in nuclear structure promote lupus autoimmunity in a mouse model

I. Tempera, Namrata Singh, Kayla A. Martin, 2016, Disease Models & Mechanisms.

Poly(ADP-ribosylated) proteins in mononuclear cells from patients with type 2 diabetes identified by proteomic studies

I. Tempera, B. Maras, A. Giorgi, 2017, Acta Diabetologica.

Characterization of catechol‐thioether‐induced apoptosis in human SH‐SY5Y neuroblastoma cells

I. Tempera, L. Mosca, E. Lendaro, 2008, Journal of neuroscience research.

Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression

I. Tempera, S. Mattiussi, L. Mosca, 2007, Infectious Agents and Cancer.

GD3 nuclear localization after apoptosis induction in HUT-78 cells.

I. Tempera, L. Mosca, E. Lococo, 2008, Biochemical and biophysical research communications.

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

I. Tempera, S. Sykes, T. Skorski, 2017, Blood advances.

Biological Effects of MC2050, a Quinazoline‐Based PARP‐1 Inhibitor, in Human Neuroblastoma and EBV‐Positive Burkitt′s Lymphoma Cells

A. Mai, I. Tempera, R. Chiaraluce, 2011, ChemMedChem.

Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage

I. Tempera, T. Skorski, Kayla A. Martin, 2018, Oncotarget.

Nuclear Lamina binds the EBV genome during latency and regulates viral gene 2 expression 3

I. Tempera, J. Madzo, Sarah Boyle, 2022 .

PARP-1 Modulates Amyloid Beta Peptide-Induced Neuronal Damage

I. Tempera, A. Fuso, B. Maras, 2013, PloS one.

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

M. Minden, G. Vassiliou, K. Matlawska-Wasowska, 2020, Cancer Research.

Human Cytomegalovirus Utilizes Multiple Viral Proteins to Regulate the Basement Membrane Protein Nidogen 1

I. Tempera, E. Fortunato, A. Zavala, 2022, Journal of virology.

Regulation of Epstein-Barr Virus OriP Replication by Poly(ADP-Ribose) Polymerase 1

I. Tempera, P. Lieberman, Chi-Ju Chen, 2010, Journal of Virology.

Chromatin organization of gammaherpesvirus latent genomes.

I. Tempera, P. Lieberman, 2010, Biochimica et biophysica acta.

Epigenetic regulation of EBV persistence and oncogenesis.

I. Tempera, P. Lieberman, 2014, Seminars in cancer biology.

Oncogenic Viruses as Entropic Drivers of Cancer Evolution

I. Tempera, P. Lieberman, 2021, Frontiers in Virology.

The nuclear lamina binds the EBV genome during latency and regulates viral gene expression

I. Tempera, J. Madzo, Sarah Boyle, 2021, bioRxiv.

Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival

Noor B. Dawany, I. Tempera, P. Lieberman, 2015, Journal of Virology.

Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4.

I. Tempera, M. Zaidi, Kayla A. Martin, 2018, Cancer research.

EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein–Barr virus-associated gastric cancer

I. Tempera, P. Lieberman, S. Soldan, 2021, Gastric Cancer.

Epigenetic Deregulation of the LMP1/LMP2 Locus of Epstein-Barr Virus by Mutation of a Single CTCF-Cohesin Binding Site

I. Tempera, P. Lieberman, Kayla A. Martin, 2013, Journal of Virology.

Interpreting the Epstein-Barr Virus (EBV) Epigenome Using High-Throughput Data

A. Arvey, I. Tempera, P. Lieberman, 2013, Viruses.

EBV Latency Types Adopt Alternative Chromatin Conformations

I. Tempera, P. Lieberman, M. Klichinsky, 2011, PLoS pathogens.

PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type

I. Tempera, Yinfei Tan, Kayla A. Martin, 2018, Journal of Virology.

PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter

J. Miranda, S. Moquin, I. Tempera, 2017, Virology.

The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity

Hideki Tanizawa, I. Tempera, P. Lieberman, 2022, Nature Communications.

Epstein–Barr virus-encoded latent membrane protein 1 and B-cell growth transformation induces lipogenesis through fatty acid synthase

I. Tempera, Sarah Johnson, Sarah Boyle, 2019, bioRxiv.

Epstein-Barr Virus-Encoded Latent Membrane Protein 1 and B-Cell Growth Transformation Induce Lipogenesis through Fatty Acid Synthase

I. Tempera, Sarah Johnson, Sarah Boyle, 2019, Journal of Virology.

CTCF Prevents the Epigenetic Drift of EBV Latency Promoter Qp

I. Tempera, P. Lieberman, Andreas Wiedmer, 2010, PLoS pathogens.

EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes

I. Tempera, P. Lieberman, P. Farrell, 2021, PLoS pathogens.

Epstein-Barr Virus-Encoded Latent Membrane Protein 1 and B-Cell Growth Transformation Induce Lipogenesis through Fatty Acid Synthase

I. Tempera, Sarah Johnson, Sarah Boyle, 2020, Journal of Virology.

Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1

I. Tempera, Yinfei Tan, J. Madzo, 2018, PLoS pathogens.

IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors

I. Tempera, M. Wasik, T. Skorski, 2017, Molecular Cancer Research.

Poly(ADP-ribosylated) proteins in β-amyloid peptide-stimulated microglial cells.

I. Tempera, B. Maras, L. Mosca, 2019, Biochemical pharmacology.

TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment.

R. Levine, D. Link, I. Tempera, 2020, Cell reports.

Three-Dimensional Chromatin Structure of the EBV Genome: A Crucial Factor in Viral Infection

I. Tempera, L. B. Caruso, Davide Maestri, 2023, Viruses.

Natural Bioactive Compounds Acting against Oxidative Stress in Chronic, Degenerative, and Infectious Diseases

I. Tempera, L. Mosca, Á. Sánchez-Lamar, 2018, Oxidative Medicine and Cellular Longevity.

EBNA1 binding and epigenetic regulation of gastrokine tumor suppressor genes in gastric carcinoma cells

Hyunna Lee, I. Tempera, P. Lieberman, 2014, Virology Journal.

Novel STIM1‐dependent control of Ca2+ clearance regulates NFAT activity during T‐cell activation

I. Tempera, Kayla A. Martin, J. Soboloff, 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1

I. Tempera, Kayla A. Martin, Lena N. Lupey, 2016, Journal of Virology.

Poly(ADP‐ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients

I. Tempera, P. Mancini, S. Morano, 2005, Journal of cellular physiology.

Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2

I. Tempera, Kayla A. Martin, M. Cesaroni, 2015, Molecular and Cellular Biology.

PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis

I. Tempera, P. Lieberman, P. Vogel, 2023, bioRxiv.

Decitabine disrupts EBV genomic epiallele DNA methylation patterns around CTCF binding sites to increase chromatin accessibility and lytic transcription in gastric cancer

I. Tempera, P. Lieberman, S. Soldan, 2023, mBio.

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

M. Minden, G. Vassiliou, K. Matlawska-Wasowska, 2021, Cancer Research.

Alterations in nuclear structure promote lupus autoimmunity in a mouse model

I. Tempera, Namrata Singh, Kayla A. Martin, 2016, Disease Models & Mechanisms.

PARP1 as an Epigenetic Modulator: Implications for the Regulation of Host-Viral Dynamics

I. Tempera, Asher A. Sobotka, 2024, Pathogens.

The CTLH Ubiquitin Ligase Substrates ZMYND19 and MKLN1 Negatively Regulate mTORC1 at the Lysosomal Membrane

J. Asara, I. Tempera, P. Lieberman, 2024, Research square.